- The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2 COVID-19 trial of Ampio Pharmaceuticals Inc's AMPE Ampion.
- The study will utilize inhaled Ampion to treat those suffering from respiratory distress due to COVID-19.
- Related Link: Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality.
- The AP-019 treatment protocol was approved with no recommended changes.
- Related: Ampio's US Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway.
- Price Action: AMPE stock is up 5.34% at $1.73 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
